血清miR-135及miR-601在胃癌患者中的表达及其诊断价值

doi:10.19401/j.cnki.1007-3639.2020.08.005

摘要/Abstract

摘要： 背景与目的：胃癌是消化内科常见的恶性肿瘤。探讨血清miR-135及miR-601在胃癌患者中的表达及其诊断价值。方法：选取2016年1月1日—2019年9月30日三亚中心医院收治的胃癌患者152例，根据胃癌病情进展及临床病理学分期分为早期胃癌组（n=62）和进展期胃癌组（n=90），Ⅰ～Ⅱ期（n=65）和Ⅲ～Ⅳ期（n=87），无淋巴结转移组（n=73）和淋巴结转移组（n=79）。另选择96例非胃癌患者作为非胃癌组，60例健康体检正常者作为对照组。采用实时荧光定量聚合酶链反应（real-time fluorescence quantitative polymerase chain reaction，RTFQ-PCR）检测各组血清miR-135及miR-601表达水平，化学发光法测定糖类抗原72-4（carbohydrate antigen 72-4，CA72-4）及糖类抗原19-9（carbohydrate antigen 19-9，CA19-9）水平，分析其对早期胃癌的诊断价值。采用Pearson相关分析来分析胃癌患者血清miR-135、miR-601水平与CA72-4及CA19-9的相关性。结果：与非胃癌组和对照组比较，胃癌组血清miR-135、miR-601、CA72-4及CA19-9水平均明显升高（P均<0.001）。进展期胃癌组血清miR-135（5.70±1.84 vs 3.83±1.12）、miR-601（11.28±3.73 vs 7.36±2.15）、CA72-4［（41.75±10.14）U/mL vs（17.82±4.93）U/mL］及CA19-9［（63.72±17.50）U/mL vs （35.84±10.36）U/mL］水平均明显高于早期胃癌组（均P<0.001）。Ⅲ～Ⅳ期胃癌患者血清miR-135（6.10±1.90 vs 3.74±1.08）、miR-601（12.14±3.92 vs 7.05±2.04）、CA72-4［（44.68±12.35）U/mL vs（16.40±4.52）U/mL］和CA19-9［（68.53±19.13）U/mL vs（33.75±10.60）U/mL］水平均明显高于Ⅰ～Ⅱ期（均P<0.001），而且Ⅱ期胃癌患者血清miR-135、miR-601、CA72-4及CA19-9水平均明显高于对照组（P<0.05）。淋巴结转移组血清miR-135（6.24±1.95 vs 3.65±0.97）、miR-601（12.60±4.13 vs 6.84±1.92）、CA72-4［（48.70±12.37）U/mL vs （14.85±4.20）U/mL］和CA19-9［（72.36±20.25）U/mL vs（31.60±10.17）U/mL］水平均明显高于无淋巴结转移组（均P<0.001）。受试者工作特征（receiver operating characteristic，ROC）曲线分析结果显示，血清miR-135、miR-601、CA72-4及CA19-9水平诊断早期胃癌的最佳截断值分别为3.78、7.14、17.63 U/mL、35.70 U/mL，四项联合诊断早期胃癌的曲线下面积（area under curve，AUC）（0.920，95% CI：0.860～0.978）最大，其灵敏度和特异度分别为98.6%和77.4%。相关分析显示，胃癌患者血清miR-135、miR-601水平与CA72-4及CA19-9均呈正相关（r=0.748，P<0.001，r=0.694，P<0.001；r=0.815，P<0.001；r=0.716，P<0.001）。结论：胃癌患者血清miR-135、miR-601、CA72-4及CA19-9水平明显升高，四项联合检测有助于提高早期胃癌的诊断价值。

关键词: 胃癌, miR-135, miR-601, 诊断价值

Abstract: Background and purpose: Gastric cancer is a common malignant tumor in gastroenterology. This study aimed to investigate the expressions of serum miR-135 and miR-601 and their diagnostic value in patients with gastric cancer. Methods: According to the progression of gastric cancer and clinical pathological stages, 152 gastric cancer patients treated in Sanya Central Hospital from Jan. 2016 to Sep. 2019 were divided into early gastric cancer group (n=62) and advanced gastric cancer group (n=90), stage Ⅰ-Ⅱ group (n=65) and stage Ⅲ-Ⅳ group (n=87), non-lymph node metastasis group (n=73) and lymph node metastasis group (n=79). In addition, 96 non-gastric cancer patients were selected as the non-gastric cancer group, and 60 healthy persons with normal physical examination were selected as the control group. Real-time fluorescence quantitative polymerase chain reaction (RTFQ-PCR) was used to detect the expression levels of serum miR-135 and miR-601 in each group, and chemiluminescence was used to determine the levels of carbohydrate antigen 72-4 (CA72-4) and carbohydrate antigen 19-9 (CA19-9), to analyze their diagnostic value in early gastric cancer. Pearson correlation analysis showed that the levels of miR-135 and miR-601 were correlated with CA72-4 and CA19-9. Results: Compared with the non-gastric cancer group and the control group, the average serum levels of miR-135, miR-601, CA72-4 and CA19-9 in gastric cancer group were significantly higher (all P<0.001). The levels of miR-135 (5.70±1.84 vs 3.83±1.12), miR-601 (11.28±3.73 vs 7.36±2.15), CA72-4［(41.75±10.14) U/mL vs (17.82±4.93) U/mL］and CA19-9 ［(63.72±17.50) U/mL vs (35.84±10.36) U/mL］in advanced gastric cancer group were significantly higher than those in early gastric cancer group (all P<0.001). The serum levels of miR-135 (6.10±1.90 vs 3.74±1.08), miR-601 (12.14±3.92 vs 7.05±2.04), CA72-4［(44.68±12.35) U/mL vs (16.40±4.52) U/mL］and CA19-9［(68.53±19.13) U/mL vs (33.75±10.60) U/mL］were significantly higher in stage Ⅲ-Ⅳ group than in stage Ⅰ-Ⅱ group (all P<0.001). The serum levels of miR-135, miR-601, CA72-4 and CA19-9 in stage Ⅱ gastric cancer patients were significantly higher than those in control group (P<0.05). The serum levels of miR-135 (6.24±1.95 vs 3.65±0.97), miR-601 (12.60±4.13 vs 6.84±1.92), CA72-4［(48.70±12.37) U/mL vs (14.85±4.20) U/mL］ and CA19-9［(72.36±20.25) U/mL vs (31.60±10.17) U/mL］ in the lymph node metastasis group were significantly higher than those in the non-lymph node metastasis group (P<0.001). The receiver operating characteristic (ROC) curve showed that the optimal cut-off values of serum miR-135, miR-601, CA72-4 and CA19-9 in the diagnosis of early gastric cancer were 3.78, 7.14, 17.63 U/mL and 35.70 U/mL, respectively. The area under the curve (AUC) (0.920, 95% CI: 0.860-0.978) in the four combined diagnosis of early gastric cancer was the largest, with the sensitivity and specificity of 98.6% and 77.4%, respectively. Correlation analysis showed that the levels of miR-135 and miR-601 were positively correlated with CA72-4 and CA19-9 respectively (r=0.748, P<0.001; r=0.694, P<0.001; r=0.815, P<0.001; r=0.716, P<0.001). Conclusion: The serum levels of miR-135, miR-601, CA72-4 and CA19-9 are significantly increased in patients with gastric cancer, and the combined detection of the four items is useful in improving the diagnostic value in early gastric cancer.

Key words: , Gastric cancer, miR-135, miR-601, Diagnostic value

田　雯 , 陈　珑 , 马艳华 , 吴开李 , 符国宏 . 血清miR-135及miR-601在胃癌患者中的表达及其诊断价值[J]. 中国癌症杂志, 2020, 30(8): 593-598.

TIAN Wen , CHEN Long , MA Yanhua , WU Kaili , FU Guohong . Expressions of serum miR-135 and miR-601 and their diagnostic value in patients with gastric cancer[J]. China Oncology, 2020, 30(8): 593-598.

[1]	张学成, 关晓辉 . Circ_0007142吸附miR-647调控CCR8基因促进胃癌细胞的上皮-间质转化和侵袭[J]. 中国癌症杂志, 2021, 31(8): 714-724.
[2]	龚　超, 陈　魁, 章德昆, 谢径峰, 吴芳华, 黄玉钿, 薛玉钦, 王力群 . 基于加权基因共表达网络分析构建胃癌转移预测模型[J]. 中国癌症杂志, 2021, 31(8): 746-753.
[3]	朱逸晖, 李　婷, 胡夕春. Trastuzumab deruxtecan的临床研究进展及展望——HER2耐药患者的新希望[J]. 中国癌症杂志, 2021, 31(8): 754-761.
[4]	郑培明, 李俊蒙, 张　鹏, 高　岚 . 巨噬细胞外泌体源miR-223促进胃癌细胞对奥沙利铂的耐药研究[J]. 中国癌症杂志, 2021, 31(5): 368-378.
[5]	刘　斌, 郑鹏远, 米　阳, 任飞飞, 高　爽, 刘　传, 李发展 . LRP8在胃癌中的表达及其在胃癌发生过程中的作用[J]. 中国癌症杂志, 2021, 31(4): 285-293.
[6]	丁平安, 张志栋, 杨沛刚, 林叶成, 田　园, 徐校胜, 吴　娟, 刘　颖, 郭洪海, 刘　洋, 王　冬, 檀碧波, 李　勇, 赵　群 . 胃癌脑膜转移的临床病理学特征及预后分析[J]. 中国癌症杂志, 2021, 31(2): 126-135.
[7]	贺国洋, 陈庆庆, 邓美静, 王高翔, 王贝玺, 王永霞, 李　巍, 千新来, 朱会芳, . DIAPH3对胃癌细胞增殖、迁移和侵袭的影响及分子机制[J]. 中国癌症杂志, 2021, 31(12): 1174-1184.
[8]	徐亦天, 黄　陈. 非血液来源液体活检在胃癌早期诊断中的研究进展[J]. 中国癌症杂志, 2021, 31(10): 936-943.
[9]	程　玉, 郝美玲, 薛　晶, 齐洁敏 . 节律因子BMAL1通过SHH信号转导通路影响胃癌MGC-803细胞的增殖[J]. 中国癌症杂志, 2020, 30(9): 661-666.
[10]	刘　鹏 , 龚　阳 , 刘道江 , 张　翔 , 张佳楠 , 杨高亮 , 方　念 . PFKFB3在胃癌中的表达及对胃癌细胞生长和凋亡的影响研究[J]. 中国癌症杂志, 2020, 30(4): 268-274.
[11]	燕飞虎 , 邹　瑞 , 王一尧 , 王芳芳 , 冉浩男 , 王　燕 . PRMT5在胃癌中的表达及其对胃癌细胞增殖、凋亡、迁移能力的影响[J]. 中国癌症杂志, 2020, 30(4): 275-283.
[12]	温培楠, 林明恕, 金　冕, 徐贤绸, 陈龙云 . 二氢杨梅素通过ERK/VEGFA/VEGFR2通路对体内外胃癌血管生成的影响[J]. 中国癌症杂志, 2020, 30(2): 113-121.
[13]	刘玉华,魏　蔚,崔淑萍. LncRNA ANCR调控miR-331表达影响胃癌细胞的生物学行为[J]. 中国癌症杂志, 2019, 29(1): 19-25.
[14]	赵青芳,关露露,吕慧芳,等. 阿帕替尼治疗晚期胃癌的疗效预测和预后分析[J]. 中国癌症杂志, 2018, 28(3): 203-209.
[15]	刘晓文,龙子雯,蔡　宏,等. 局部进展期胃癌术前化疗与术前放化疗的对比研究[J]. 中国癌症杂志, 2018, 28(10): 762-768.

血清miR-135及miR-601在胃癌患者中的表达及其诊断价值

Expressions of serum miR-135 and miR-601 and their diagnostic value in patients with gastric cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价